New hope for HIV patients who failed long-acting shots: switching to a daily pill

NCT ID NCT07620652

Not yet recruiting Disease control Sponsor: Cristina Mussini Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This study looks at whether switching to a daily pill containing bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) can help people with HIV who previously did not respond to a long-acting injectable treatment (CAB/RPV LAI). The study includes 30 adults and will check if the switch leads to undetectable virus levels at 24 and 48 weeks. It also monitors safety and immune system changes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF)
What this could lead to: If successful, this could offer a new treatment option for people with HIV who have not responded to a specific long-acting injectable regimen.
What could go wrong: This is a small pilot study with only 30 participants, so results may not apply to everyone. The treatment may not work for those with certain drug resistance mutations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTION

Contacts and locations

Locations

AOU Modena

Modena, MO, 41124, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.